Trials / Completed
CompletedNCT01083810
Evaluation of Kaletra Therapy Over the Long-term
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 284 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Long term observation of patients under lopinavir/ritonavir containing therapy
Detailed description
Three to five year observation of lopinavir/ritonavir therapy. Reporting groups are 1) therapy-naïve patients (144 weeks), 2) therapy-experienced but protease inhibitor naïve patients (240 weeks,) and 3) non-B subtype infected patients (240 weeks). These three groups of participants with HIV-1 infection were at first registered as three different studies: KAL1RO (this study, NCT01083810, n=137), KAL2RO /KAL5RO (NCT01083836, n=92), and KAL6RO (NCT01081470, n=55) but were now reconciled under KAL1RO (NCT01083810) as a single study with three reporting groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir/Ritonavir (Kaletra) | 3 capsules 2xdaily or 2 tablets 2xdaily Kaletra |
Timeline
- Start date
- 2001-06-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2010-03-10
- Last updated
- 2011-08-11
- Results posted
- 2011-07-29
Locations
90 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01083810. Inclusion in this directory is not an endorsement.